Page last updated: 2024-08-21

pyrazines and Bile Duct Cancer

pyrazines has been researched along with Bile Duct Cancer in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (66.67)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Moolmuang, B; Ruchirawat, M	1
Kariya, R; Matsuda, K; Okada, S; Taura, M; Vaeteewoottacharn, K; Wongkham, C; Wongkham, S	1
Alpaugh, RK; Cheng, JD; Cohen, SJ; Cooper, H; Denlinger, CS; Engstrom, PF; Lewis, NL; Li, T; Meropol, NJ; Weiner, LM; Wright, JJ	1

Trials

1 trial(s) available for pyrazines and Bile Duct Cancer

Article	Year
A phase II trial of the proteasome inhibitor bortezomib in patients with advanced biliary tract cancers. Clinical colorectal cancer, 2014, Volume: 13, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Boronic Acids; Bortezomib; Cholangiocarcinoma; Disease Progression; Female; Follow-Up Studies; Gallbladder Neoplasms; Humans; Male; Middle Aged; Proteasome Inhibitors; Pyrazines; Survival Rate; Time Factors; Treatment Outcome	2014

Article

Year

A phase II trial of the proteasome inhibitor bortezomib in patients with advanced biliary tract cancers.

Clinical colorectal cancer, 2014, Volume: 13, Issue:2

Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Boronic Acids; Bortezomib; Cholangiocarcinoma; Disease Progression; Female; Follow-Up Studies; Gallbladder Neoplasms; Humans; Male; Middle Aged; Proteasome Inhibitors; Pyrazines; Survival Rate; Time Factors; Treatment Outcome

2014

Other Studies

2 other study(ies) available for pyrazines and Bile Duct Cancer

Article	Year
The antiproliferative effects of ataxia-telangiectasia mutated and ATM- and Rad3-related inhibitions and their enhancements with the cytotoxicity of DNA damaging agents in cholangiocarcinoma cells. The Journal of pharmacy and pharmacology, 2021, Mar-01, Volume: 73, Issue:1 Topics: Antineoplastic Agents; Ataxia Telangiectasia; Ataxia Telangiectasia Mutated Proteins; Bile Duct Neoplasms; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; DNA Damage; Humans; Morpholines; Protein Kinase Inhibitors; Pyrazines; Pyrones; Sulfones; Tumor Suppressor Protein p53	2021
Perturbation of proteasome function by bortezomib leading to ER stress-induced apoptotic cell death in cholangiocarcinoma. Journal of cancer research and clinical oncology, 2013, Volume: 139, Issue:9 Topics: Animals; Antineoplastic Agents; Apoptosis; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Cholangiocarcinoma; Endoplasmic Reticulum Stress; Humans; Janus Kinase 3; Luciferases; Mice; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; NF-kappa B; Proteasome Endopeptidase Complex; Pyrazines; Transcription Factor CHOP; Tumor Cells, Cultured; Unfolded Protein Response	2013

Article

Year

The antiproliferative effects of ataxia-telangiectasia mutated and ATM- and Rad3-related inhibitions and their enhancements with the cytotoxicity of DNA damaging agents in cholangiocarcinoma cells.

The Journal of pharmacy and pharmacology, 2021, Mar-01, Volume: 73, Issue:1

Topics: Antineoplastic Agents; Ataxia Telangiectasia; Ataxia Telangiectasia Mutated Proteins; Bile Duct Neoplasms; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; DNA Damage; Humans; Morpholines; Protein Kinase Inhibitors; Pyrazines; Pyrones; Sulfones; Tumor Suppressor Protein p53

2021

Perturbation of proteasome function by bortezomib leading to ER stress-induced apoptotic cell death in cholangiocarcinoma.

Journal of cancer research and clinical oncology, 2013, Volume: 139, Issue:9

Topics: Animals; Antineoplastic Agents; Apoptosis; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Cholangiocarcinoma; Endoplasmic Reticulum Stress; Humans; Janus Kinase 3; Luciferases; Mice; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; NF-kappa B; Proteasome Endopeptidase Complex; Pyrazines; Transcription Factor CHOP; Tumor Cells, Cultured; Unfolded Protein Response

2013